Loading company…
SpliceBio develops gene therapies built on its protein splicing technology, aimed at rare genetic diseases.
Founded in 2012 in Barcelona, Spain, SpliceBio, S.L. develops gene therapy solutions using its proprietary protein splicing technology for rare genetic diseases. The company was established by Sílvia Frutos. In June 2025 it raised EUR 118 million in Series B funding co-led by EQT Life Sciences and Sanofi Ventures, with Roche Venture Fund also participating, and plans to use it to advance phase I/II trials of its lead compound, SB-007.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in